Investigation of Anti Receptor Advanced Glycation End Product Effect in Pericyte Loss Prevention in Diabetic Retinopathy

Ramzi Amin, Rachmat Hidayat, Ria Mutiara


Diabetic retinopathy is a microvascular complication that is found due to the condition of diabetes mellitus. This study was aimed to investigate the effect of anti receptor advanced glycation end products on survival pericytes by assessing apoptotic activity and the number of pericytes. This research is an in vivo study that used Sprague-Dawley rats as a study object. The rats were grouped into three groups, group 1 was a control group without induced diabetes, group 2 was rats with induced diabetes, and group 3 was diabetes-induced rats who received anti receptor advanced glycation end products injection. Advanced glycation end-products accumulation was evaluated by the immunohistochemistry method. Apoptotic cells are detected by conjugated streptavidin peroxidase in retinal vascular digests. The diabetic rats showed a 32% increase in body weight than the control group from the metabolic parameter. While anti receptor advanced glycation end group only gained weight 28% higher than the standard group. The immunohistochemistry examination showed that the accumulation of advanced glycation end products was found in the retinal vessels and inner neural retina in the diabetic retinopathy group. In conclusion, anti receptor advanced glycation end products administration can prevent pericyte cell loss in retinal vessels via inhibition of apoptosis and oxidative stress due to inhibition of advanced glycation end products and their receptor interactions in pericyte cells.


Keywords: anti receptor advanced glycation end, pericyte cell, retinal vessel, diabetic retinopathy, in vivo study.

Full Text:



WANG W., & LO A. Diabetic retinopathy: Pathophysiology and treatments. International Journal of Molecular Sciences, 2018, 19(6): 1816.

MADONNA R., BALISTRERI C. R., GENG Y.-J., and RAFFAELE D. C. Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. Vascular Pharmacology, 2017, 90: 1-7.

FAWWAD A., MUSTAFA N., BIN ZAFAR A., and KHALID M. Incidence of microvascular complications of type 2 diabetes: A 12 year longitudinal study from Karachi-Pakistan. Pakistan Journal of Medical Sciences, 2018, 34: 1058-1063.

BUTT A., MUSTAFA N., FAWWAD A., ASKARI S., HAQUE M. S., TAHIR B., and BASIT A. Relationship between diabetic retinopathy and diabetic nephropathy; A longitudinal follow up study from a tertiary care unit of Karachi, Pakistan. Diabetes and Metabolic Syndrome, 2020, 14: 1659-1663.

DORCELY B., KATZ K., JAGANNATHAN R., CHIANG S. S., OLUWADARE B., GOLDBERG I. J., and BERGMAN M. Novel biomarkers for prediabetes, diabetes and associated complications. Diabetes, Metabolic Syndromes and Obesity: Targets and Therapy, 2017, 10: 345-361.

KERN T. S., ANTONETTI D. A., and SMITH L.E.H. Pathophysiology of diabetic retinopathy contribution and limitations of laboratory research. Ophthalmic Research, 2019, 62: 196-202.

SINCLAIR S. H., & SCHWARTZ S. S. Diabetic retinopathy - An underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes. Frontiers in Endocrinology, 2019, 18: 43-48.

GIURDANELLA G., LAZZARA F., CAPORARELLO N., LUPO G., ANFUSO C. D., EANDI C. M., LEGGIO G. M., DRAGO F., BUCOLO C., and SALOMONE S. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochemical Pharmacology, 2017, 142: 145-154.

PRASAD K., & MISHRA M. AGE-RAGE stress, stressors, and antistressors in health and disease. International Journal Angiology, 2018, 27: 1-12.

XU J., CHEN L.-J., YU J., WANG H.-J., ZHANG F., LIU Q., and WU J. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cellular Physiology and Biochemistry, 2018, 48: 705-717.

ZHAO H., & CHAPPELL J. C. Microvascular bioengineering: a focus on pericytes. Journal of Biological Engineering, 2019, 13: 26.

SALEH I., MARITSKA Z., PARISA N., and HIDAYAT R. Inhibition of receptor advanced glycation end products as new promising strategy treatment in diabetic retinopathy. Open Access Macedonian Journal of Medical Sciences, 2019, 7: 3921-3924.

LI J., CAO Y., LIU W. WANG, Q., QIAN Y., and LU P. Correlations among diabetic microvascular complications: A systematic review and meta-analysis. Scientific Reports, 2019, 9: 31-37.

CHUNG Y. R., CHOI J. A., KOH J. Y., and YOON Y. H. Ursodeoxycholic acid attenuates endoplasmic reticulum stress related retinal pericyte loss in streptozotocin-induced diabetic mice. Journal of Diabetes Research, 2017, 2017: 1763292.

KANDA A., DONG Y., NODA K., SAITO W., and ISHIDA S. Advanced glycation end products link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy. Scientific Reports, 2017, 7: 16168.

LAI D.-W., LIN K.-H., SHEU W. H.-H., LEE M.-R., CHEN C.-Y., LEE W.-J., HUNG Y.-W., SHEN C.-C., CHUNG T.-J., LIU S.-H., and SHEU M.-L. TPL2 (Therapeutic targeting tumor progression locus-2)/ATF4 (activating transcription factor-4)/SDF1alpha (chemokine stromal cell-derived factor-alpha) axis suppresses-diabetic retinopathy. Circulation Research, 2017, 121: 37-52.

ZHANG Y., WANG L., ZHANG Y., SUN Q., XIA F., WANG R., and LIU L. Nogo-B promotes angiogenesis in proliferative diabetic retinopathy via VEGF/PI3K/Akt pathway in an autocrine manner. Cellular Physiology and biochemistry, 2017, 43: 1742-1754.


  • There are currently no refbacks.